Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank Andreas Zueiter for excellent documentation assistance.

This work was supported by the Bundesministerium f r Bildung und Forschung (BMBF) [grant 01KN1106]; and by Merck Serono GmbH (grant and drug donation to AE and BvT).

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

BvT and AE received support from Merck Serono GmbH (grant and drug donation).

All remaining authors have declared no conflicts of interest.